17 December 2004
CLINICAL AND REGULATORY CHANGES AT ASTRAZENECA
– GUIDANCE FROM SIR TOM McKILLOP, CHIEF EXECUTIVE
AstraZeneca is committed to the development of innovative medicines but Exanta and Iressa, two products based on breakthrough science, have suffered setbacks.

22 November 2004
ASTRAZENECA AND CAMBRIDGE ANTIBODY TECHNOLOGY ANNOUNCE MAJOR STRATEGIC ALLIANCE TO DISCOVER AND DEVELOP HUMAN ANTIBODY THERAPEUTICS IN INFLAMMATORY DISORDERS
AstraZeneca makes £75 million upfront equity investment. Complements earlier alliance with Abgenix, Inc. in oncology.

12 October 2004
ASTRAZENECA IN THE US CELEBRATES 20 YEARS OF PROMOTING EXCELLENCE IN CHEMISTRY
AstraZeneca, one of the world’s leading investors in pharmaceutical research and development, today celebrates its 20th year of supporting talented academic researchers through its annual Excellence in Chemistry Awards program. more

25 May 2004
NEW STUDY SHOWS THAT ASTHMA VARIABILITY STILL EXISTS DESPITE STRICT ADHERENCE TO NATIONAL MANAGEMENT GUIDELINES
Patients continute to be symptomatic
A study presented today at the 100th International Conference of the American Thoracic Society in Orlando shows that many patients enrolled in a clinical study that followed the asthma treatment guidelines outlined by the National Asthma Education and Prevention Program and published by the National Heart, Lung and Blood Institute (NHLBI), still suffered from asthma symptoms and poor lung function between clinic visits, despite simultaneous decreases of many of the serious events associated with asthma. The guidelines include recommendations that support use of long-term controller asthma medications to achieve and maintain control for persistent asthma. more

4 May 2004
JOINED FORCES TO IMPROVE CHOLESTEROL LOWERING DRUG COMPLIANCE
One of the largest insurers in the US and AstraZeneca will conduct a joint study to evaluate how technology can improve patient medication compliance. This study will measure how Voice Activated Technology (VAT) can help patients better understand and monitor their medication and support patient needs. The VAT study will address issues such as motivation, self-confidence and barriers, while evaluating what prompts patients to take their cholesterol-lowering medication as directed and follow their course of treatment.

20 April 2004
ASTRAZENECA STRENGTHENS RESEARCH & DEVELOPMENT CAPABILITIES IN THE UNITED STATES THROUGH CONSIDERABLE INVESTMENT IN WILMINGTON, DELAWARE
AstraZeneca today celebrates the opening of a state-of-the-art Automated Compound Management Facility (ACMF) at their Wilmington R&D campus. Part of a four-year, $165 million investment in US research facilities, this latest $13 million addition is one of four new AstraZeneca drug discovery research facilities of its kind worldwide.

31 March 2004
ASTRAZENECA CEO CALLS FOR INTEGRATED BIOMEDICAL RESEARCH STRATEGY AT AMS LECTURE
Sir Tom McKillop, Chief Executive AstraZeneca PLC, today will call for an integrated biomedical research strategy and a European Market Place ready to reward innovation to reverse Europe’s relative decline in biomedical research. Sir Tom McKillop will make these remarks when he delivers the Second Annual Forum Lecture to the Academy of Medical Sciences (AMS).

16 March 2004
ASTRAZENECA ANNOUNCES LATEST PHASE OF UK £1 BILLION INVESTMENT PROGRAMME
AstraZeneca has announced two major investments in the UK with the imminent opening of major new facilities in Alderley Park, Macclesfield, Cheshire, and additional investment to support the development of its research site in Charnwood, Loughborough, Leicestershire. These latest developments will mean that AstraZeneca’s investment in the UK (from 1999 and planned until 2006), will have approached a potential £1 billion, with the creation of well over 550 new science related jobs.